IPO Databook: Biovie (BIVI US) - Aug 2026

144 Views19 Jul 2026 10:02

SUMMARY

BioVie Inc. is a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative disorders and advanced liver disease, offering shares and warrants.
Phase 2b SUNRISE-PD trial for Parkinson's disease met primary endpoint with statistically significant reduction in neuroinflammation in August 2026.
The auditor's report includes an explanatory paragraph about substantial doubt concerning the Company's ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream